CHMA - Chiasma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.6500
-0.1000 (-2.67%)
As of 12:05PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.7500
Open3.7600
Bid3.61 x 1800
Ask3.66 x 1100
Day's Range3.5200 - 3.7600
52 Week Range1.2000 - 4.8660
Volume36,766
Avg. Volume84,183
Market Cap89.172M
Beta (3Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-1.20
Earnings DateMar 18, 2019 - Mar 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
Trade prices are not sourced from all markets
  • GlobeNewswire19 days ago

    Chiasma Previews Important Upcoming Milestones

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today previewed anticipated upcoming corporate milestones and commented on the significant progress made by the company in 2018. “During 2018, we completed the required enrollment in both of our Phase 3 clinical trials of our investigational octreotide capsules product candidate, which we have conditionally trade-named Mycapssa®, and with those trials progressing as planned, we believe we have set the stage for a catalyst-rich 2019 including the announcement of topline data evaluating Mycapssa’s efficacy as potentially the first oral somatostatin analog for the maintenance therapy of adult acromegaly patients,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.

  • Do Directors Own Chiasma, Inc. (NASDAQ:CHMA) Shares?
    Simply Wall St.last month

    Do Directors Own Chiasma, Inc. (NASDAQ:CHMA) Shares?

    Every investor in Chiasma, Inc. (NASDAQ:CHMA) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease Read More...

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Associated Press2 months ago

    Chiasma: 3Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 31 cents. In the final minutes of trading on Thursday, the company's shares hit $4.20. A year ago, they were trading ...

  • GlobeNewswire2 months ago

    Chiasma Reports Third Quarter 2018 Results

    Topline Data from Phase 3 CHIASMA OPTIMAL Trial of Octreotide Capsules, Conditionally Trade-Named MYCAPSSA®, Anticipated by September 2019 Company randomizes 80th patient.

  • GlobeNewswire3 months ago

    Chiasma Supports Acromegaly Awareness Day

    Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. “Today, we acknowledge the acromegaly patients, their families and advocates, as well as the clinical thought leaders who have been instrumental in our efforts to develop an oral treatment alternative for this rare but serious disease,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.

  • Benzinga4 months ago

    The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...

  • One Thing To Consider Before Buying Chiasma Inc (NASDAQ:CHMA)
    Simply Wall St.4 months ago

    One Thing To Consider Before Buying Chiasma Inc (NASDAQ:CHMA)

    If you’re interested in Chiasma Inc (NASDAQ:CHMA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impactRead More...

  • Associated Press5 months ago

    Chiasma: 2Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 36 cents per share. In the final minutes of trading on Thursday, the company's shares hit $1.25. A year ago, they were trading at $1.45. _____ ...

  • ACCESSWIRE10 months ago

    Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018

    Stock Monitor: Akebia Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Chiasma, Inc. (NASDAQ: CHMA ). If ...

  • Want To Invest In Chiasma Inc (NASDAQ:CHMA)? Here’s How It Performed Lately
    Simply Wall St.10 months ago

    Want To Invest In Chiasma Inc (NASDAQ:CHMA)? Here’s How It Performed Lately

    Examining Chiasma Inc’s (NASDAQ:CHMA) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, which isRead More...